scispace - formally typeset
M

Mark M. Davis

Researcher at Stanford University

Publications -  623
Citations -  84251

Mark M. Davis is an academic researcher from Stanford University. The author has contributed to research in topics: T cell & T-cell receptor. The author has an hindex of 144, co-authored 581 publications receiving 74358 citations. Previous affiliations of Mark M. Davis include Washington University in St. Louis & University of Chicago.

Papers
More filters
Journal ArticleDOI

Preclinical study of the cyclodextrin-polymer conjugate of camptothecin CRLX101 for the treatment of gastric cancer.

TL;DR: A nanoparticle assembly containing cyclodextrin-based polymer and camptothecin is described, resulting in increased bioavailability of camptethecin, an effective but toxic anti-cancer agent.
Journal ArticleDOI

Select sequencing of clonally expanded CD8+ T cells reveals limits to clonal expansion.

TL;DR: While there is no relationship between expression profiles and clonal expansion in iNKT or MAIT cells, highly expanded conventional CD8+ T cells down-regulate the interleukin 2 (IL-2) receptor alpha (IL2RA, or CD25) protein and show signs of senescence, which suggests inherent limits toClonal expansion that act to diversify the T cell response repertoire.
Journal ArticleDOI

A role for “self” in T-cell activation

TL;DR: Recent experimental data is highlighted that provides insights into the initiation of T-cell activation and the main controversies and uncertainties in this area are discussed.
Journal ArticleDOI

Distinct molecular mechanisms account for the specificity of two different T-cell receptors.

TL;DR: Analysis of the thermodynamics of the interactions between the D3 T-cell receptor (TCR) and its natural ligand, an HIV peptide bound to a HLA-A*0201 (HLA-A2) major histocompatibility complex (MHC) ...
Journal ArticleDOI

Plasmablast-derived polyclonal antibody response after influenza vaccination.

TL;DR: This assay is particularly useful for studying vaccine/infection-induced antibodies against antigens that might have previously circulated, such as antibody responses to rotavirus, dengue or influenza viruses in which cross-reactive antibodies against different virus serotypes/subtypes play a critical role in immunity and/or pathogenesis.